- Conditions
- Pigmented Villonodular Synovitis, Tenosynovial Giant Cell Tumor
- Interventions
- FPA008
- Biological
- Lead sponsor
- Five Prime Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Santa Monica, California • Stanford, California + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–7
of 7
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Pancreatic Cancer Stage IV
- Interventions
- Gemcitabine, Nivolumab 10 MG/ML Intravenous Solution [OPDIVO], Cabiralizumab
- Drug
- Lead sponsor
- Hitendra Patel
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Advanced Pancreatic Cancer
- Interventions
- Cabiralizumab, Nab-paclitaxel, Onivyde, Nivolumab, Fluorouracil, Gemcitabine, Oxaliplatin, Leucovorin, Irinotecan Hydrochloride
- Biological · Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 205 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 19
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 13 more
- Conditions
- Cancer
- Interventions
- Nivolumab, Cabiralizumab, Urelumab, Stereotactic Body Radiation Therapy
- Drug · Radiation
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Peripheral T Cell Lymphoma
- Interventions
- Nivolumab, cabiralizumab
- Drug
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 3
- States / cities
- Ann Arbor, Michigan • Columbus, Ohio • Madison, Wisconsin
- Conditions
- Advanced Cancer
- Interventions
- Nivolumab, Relatlimab, Cabiralizumab, Ipilimumab, IDO1 Inhibitor, Radiation Therapy
- Biological · Drug · Radiation
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Baltimore, Maryland • Pittsburgh, Pennsylvania
- Conditions
- Advanced Solid Tumors, Head and Neck Cancer, Pancreatic Cancer, Ovarian Cancer, Renal Cell Carcinoma, Malignant Glioma, Non-small Cell Lung Cancer
- Interventions
- Cabiralizumab, Nivolumab
- Biological
- Lead sponsor
- Five Prime Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 313 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 39
- States / cities
- Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 27 more